Why does tranexamic acid work so well in acute bleeding, yet fail repeatedly in prophylactic settings?

New research out of Semmelweis University (Biomolecules, May 2026) is helping explain one of the most clinically frustrating questions in haemostasis.

Using #ClotPro alongside confocal microscopy and electron microscopy, the authors found that TXA incorporated into a clot before fibrinolytic challenge actually thickened fibrin fibres and enlarged pore structure — paradoxically accelerating lysis at physiological plasminogen concentrations. When TXA and tPA were present simultaneously (the therapeutic scenario), ClotPro consistently showed prolonged lysis time and increased clot firmness across all plasminogen concentrations.

The take-home: TXA efficacy is governed not just by dose, but by timing and the plasminogen/TXA balance within the clot microenvironment. This debate is far from settled — and at #Haemoview, it's exactly the kind of evolving science we follow closely to ensure the clinicians we support are equipped with the tools and evidence to make informed decisions in real time.

For those managing trauma, cardiac surgery, or obstetric haemorrhage — this is a compelling argument for viscoelastic monitoring. Knowing whether TXA is working in your patient matters as much as giving it.

Read the article here :https://www.mdpi.com/2218-273X/16/5/696